Cationically modified inhalable nintedanib niosomes : enhancing therapeutic activity against non-small-cell lung cancer
Aim: This study was designed to develop and test nintedanib-loaded niosomes as inhalable carriers for enhancing its therapeutic efficacy via localized drug accumulation and addressing issues such as low bioavailability and severe toxicity. Methods: Niosomes were prepared by thin-film hydration method and were evaluated for in vitro therapeutic effectiveness in lung cancer cells. Results: The optimized niosomal formulation displayed optimized vesicle size, controlled and extended release of drug, and efficient aerodynamic properties indicating its suitability as an aerosolized formulation. In vitro studies revealed significantly superior cytotoxicity of nintedanib-loaded niosomes which was further validated by 3D spheroids. Conclusion: These findings establish the effectiveness of niosomes as inhalable delivery carriers which could serve as a promising strategy for delivery of nintedanib to treat several lung cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 17(2022), 13 vom: 25. Juni, Seite 935-958 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
K Shukla, Snehal [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.10.2022 Date Revised 02.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2022-0045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345230205 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345230205 | ||
| 003 | DE-627 | ||
| 005 | 20231226024607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2022-0045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345230205 | ||
| 035 | |a (NLM)36004583 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a K Shukla, Snehal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cationically modified inhalable nintedanib niosomes |b enhancing therapeutic activity against non-small-cell lung cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.10.2022 | ||
| 500 | |a Date Revised 02.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: This study was designed to develop and test nintedanib-loaded niosomes as inhalable carriers for enhancing its therapeutic efficacy via localized drug accumulation and addressing issues such as low bioavailability and severe toxicity. Methods: Niosomes were prepared by thin-film hydration method and were evaluated for in vitro therapeutic effectiveness in lung cancer cells. Results: The optimized niosomal formulation displayed optimized vesicle size, controlled and extended release of drug, and efficient aerodynamic properties indicating its suitability as an aerosolized formulation. In vitro studies revealed significantly superior cytotoxicity of nintedanib-loaded niosomes which was further validated by 3D spheroids. Conclusion: These findings establish the effectiveness of niosomes as inhalable delivery carriers which could serve as a promising strategy for delivery of nintedanib to treat several lung cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a aerosol | |
| 650 | 4 | |a cationically modified vesicles | |
| 650 | 4 | |a inhalable delivery carrier | |
| 650 | 4 | |a nintedanib | |
| 650 | 4 | |a niosomes | |
| 650 | 4 | |a non-small-cell lung cancer | |
| 650 | 4 | |a tyrosine kinase | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a nintedanib |2 NLM | |
| 650 | 7 | |a G6HRD2P839 |2 NLM | |
| 700 | 1 | |a Nguyen, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, Mimansa |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Vivek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 17(2022), 13 vom: 25. Juni, Seite 935-958 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:13 |g day:25 |g month:06 |g pages:935-958 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2022-0045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 13 |b 25 |c 06 |h 935-958 | ||